comparemela.com

Latest Breaking News On - Irish government disruptive technologies innovation fund - Page 2 : comparemela.com

Poolbeg Pharma Next Generation Oral Vaccine Programme Entering the Next Phase

Poolbeg Pharma Next Generation Oral Vaccine Programme Entering the Next Phase

Poolbeg pharmaJeremy skillingtonTed lavelleAidan fitzsimonsEncovac consortiumSchool of biomolecularProfessor ed lavelle at trinity college dublinMcclean at university college dublinOral vaccine programmeTrinity college dublinPoolbeg oral vaccine programmeUniversity college dublinIrish government disruptive technologies innovation fundIrish governmentDisruptive technologies innovation fundGrant agreements

Poolbeg Pharma Plc Oral Vaccine Programme Moves Forward

Poolbeg Pharma Plc Oral Vaccine Programme Moves Forward

Jeremy skillingtonAidan fitzsimonsGeneration oral vaccine programme advancing through nonMcclean at university college dublinProfessor ed lavelle at trinity college dublinIrish government disruptive technologies innovation fundEncovac consortiumPoolbeg oral vaccine programmeOral vaccine programmeIrish governmentDisruptive technologies innovation fundGrant agreementsAnabio technologiesAssociate professor siobhUniversity college dublinProfessor ed lavelle

Galway medtech s device to treat colorectal condition granted US patent

Last year, Signum Surgical raised €2.9m to commercialise the BioHealx device. The tech has now been patented in the US.

Moshe zilversmitIrish government disruptive technologies innovation fundUs patent officeNational university of ireland bioinnovateHalo business angel networkSignum surgicalNational universityIrish governmentDisruptive technologies innovation

Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022

Results for the year ended 31 December 2022 Significant milestones reached, well capitalised and positioned for future growth LONDON, UK / ACCESSWIRE / March

City ofUnited kingdomHong kongUnited statesLinkedin poolbegpharmaPoolbeg immunomodulatorsJeremy skillingtonPoolbeg pharmaCathal frielArtificial intelligence ai programmeInternational financial reporting standardsUniversity of warwickTrademark officeInvestor meet companyEuropean patent officeA us centers for disease

Licencing deal paves way for new treatment methods for metabolic diseases

Poolbeg Pharma wants to look into the potential of microencapsulation and nanoencapsulation oral delivery technologies for treating chronic conditions.

Jeremy skillingtonPoolbeg pharmaIrish government disruptive technologies innovation fundAnabio technologiesGlucagon like peptideIrish governmentDisruptive technologies innovation

vimarsana © 2020. All Rights Reserved.